Effects of canagliflozin on the glycemic control and plasma GLP-1 levels.
Not Applicable
- Conditions
- Type 2 diabetes mellitus
- Registration Number
- JPRN-UMIN000018345
- Lead Sponsor
- akakinen clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 45
Inclusion Criteria
Not provided
Exclusion Criteria
1) Type 1 diabetes, diabetes due to a pancreatic disorder, or secondary diabetes due to conditions 2) Application of contraindications contained in the package insert 3) Severe renal function disorder 4)BMI is < 22kg/m2 5) Under treatment with insulin,GLP-1 analog, or SGLT2 inhibitor 6) Pregnant women, women suspected of being pregnant, or lactating women 7) Participation in the study is judged by the investigator or sub-investigator as inappropriate for any other reason
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Postprandial changes in glucose and GLP-1 levels after 12 weeks of treatment with canagliflozin
- Secondary Outcome Measures
Name Time Method 1) Change in glycemic parameters, body weight, waist circumference, and glucagon after 12 weeks of treatment with canagliflozin. 2) Continuous glucose monitoring